Exclusive distribution agreement for the whole new BIOCERA-VET line in Spain Nuzoa's sales force in support of commercialization Commercial launch earlier than anticipated Regulatory
Positive safety and efficacy results for BIOCERA-VET (arthrodesis and canine osteosarcoma) and VISCO-VET (canine osteoarthritis) Initiation of the pivotal European multicentric clinical study
Commercial launch of BIOCERA-VET product line in United Kingdom and Ireland in accordance with the development plan announced by the company Participation at the British Small Animal Veterinary
Positive BIOCERA-VET arthrodesis data will be presented in collaboration with Dr. Guillaume Ragetly (ECVS, ACVS, PhD; France) at the US Veterinary Orthopedic Society The annual conference
04.02.2022 - Regulatory News: TheraVet (Paris:ALVET) (Brussels:ALVET) (ISIN: BE0974387194 - ticker: ALVET), a pioneering company in the management of osteoarticular diseases in pets, announces today the presentation in collaboration with Dr. Guillaume Ragetly .